TRAC team grows again

Cornwall-based regulatory affairs specialist appoints three new members of staff

Natalie Grogan, Debbie Finlay and Mike May have joined Cornwall's TRAC, which works with pharmaceutical companies to ensure that they are meeting their regulatory responsibilities.

Grogan takes the role of marketing manager, having relocated from Manchester where she has spent the last seven years in the marketing department of fashion and footwear home retailer JD Williams & Co.

Finlay and May boost TRAC’s Regulatory Affairs team, where they will be working on a range of projects for clients across Europe.

After spending 12 years living and working in Boston, US, Finlay returned to Cornwall in 2005 and graduated with a degree in Biological Science in 2009.

May graduated from Indiana State University in 2007 before relocating to study at the University of Plymouth where he gained a BSc in Human Biosciences.

‘We are delighted to have secured the services of Natalie, Debbie and Mike in the latest part of our development programme. They bring not only experience but also enthusiasm and a real desire to be part of the TRAC success story,’ said TRAC director Sarah Trethowan.

You may also like

Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Regulatory

NOAH calls for Veterinary Medicines Agreement amid concerns over Northern Ireland veterinary medicines supply changes

With EU regulations set to apply fully from 1 January 2026, Northern Ireland could see 10-15% of veterinary medicines discontinued. Industry and government are working on mitigation schemes to protect animal health and ensure continued access to essential treatments
Regulatory

Piramal Pharma Solutions’ bioconjugates facility in Grangemouth, UK, receives updated MHRA GMP certificates

These certificates cover all activities conducted in the site’s Helix building, including its supporting warehouse and laboratory areas
Regulatory

UK-US pharma deal removes tariffs and boosts access to innovative medicines

The UK has secured a zero-tariff agreement on pharmaceutical exports to the US, alongside major reforms to accelerate NHS access to new treatments
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Regulatory

FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment

The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Regulatory

European Commission approves Teva denosumab biosimilars PONLIMSI and DEGEVMA

The two biosimilars to Prolia and Xgeva will expand access to important bone health treatments across Europe and bolster Teva's strong biosimilars portfolio
Subscribe now